Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Jan 14-possible USPTO decision?

As you say, there's plenty to pick at.

However, IMO, with respect to this particular scab, the problem comes in that the company has admitted that there is no auditing function in place that would ascertain and/or prevent Alliancense from simply passing that 10% interest charge (or more for hat matter), though to PDS, and in essence cover the tab for TPL, and costing PTSC again in a diminished distribution from PDS due to higher expenses.

Hardly the sweetheart deal you intimate.

It's futher unfortunate, that it speaks to the condition that TPL is currently in that they need a credit line from PTSC to meet payroll. I'm afraid it's more likely PTSC had no choice BUT to make this loan to maintain the viability of the MMP.

Share
New Message
Please login to post a reply